Open AccessDiabetic ketoacidosis shortly after COVID ‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD ‐1 and CTLA ‐4 inhibitors: A case report
Author(s) -
Makiguchi Tomonori,
Fukushima Takashi,
Tanaka Hisashi,
Taima Kageaki,
Takayasu Shinobu,
Tasaka Sadatomo
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14352
Subject(s) - medicine , vaccination , immunogenicity , immunology , diabetic ketoacidosis , adverse effect , immune system , lung cancer , diabetes mellitus , endocrinology
We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS‐CoV‐2 (COVID‐19) vaccination in a 65‐year‐old woman with non–small‐cell lung cancer under a combination treatment of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors. She had no history of diabetic mellitus. A few days after the second shot of COVID‐19 vaccination, she developed DKA. We speculate that the immune‐related adverse event and immunogenicity of vaccination synergistically induced DKA.